|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM168614227 |
| 003 |
DE-627 |
| 005 |
20250208014737.0 |
| 007 |
tu |
| 008 |
231223s2007 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0562.xml
|
| 035 |
|
|
|a (DE-627)NLM168614227
|
| 035 |
|
|
|a (NLM)17321799
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Saverino, Daniele
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Soluble CTLA-4 in autoimmune thyroid diseases
|b relationship with clinical status and possible role in the immune response dysregulation
|
| 264 |
|
1 |
|c 2007
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.06.2007
|
| 500 |
|
|
|a Date Revised 10.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a CTLA-4 molecule, expressed by activated T and B lymphocytes, transduces an inhibitory signal. Increasing evidence showed CTLA-4 gene as an important susceptibility locus for autoimmune endocrinopathies and other autoimmune disorders. The aim is to evaluate the augmented sCTLA-4 serum levels in different autoimmune thyroid diseases when compared with normal donors or with non-autoimmune hyperthyroidism and to investigate the functional activities and suggest the possible pathogenetic role of sCTLA-4. We demonstrate the presence of a soluble form of CTLA-4 in 59/90 sera from patients with autoimmune thyroid diseases (both Graves' disease and autoimmune thyroiditis). sCTLA-4 levels were not related to specific clinical manifestations, such as clinical thyroid status (hypo- or hyperthyroidism), circulating thyroid hormones, or other clinical features (ophthalmopathy). sCTLA-4 production does not seem to be affected by disease evolution during time. We showed that sCTLA-4 from sera of patients with thyroid autoimmunity is able to bind its physiological ligands CD80/CD86 and displays functional activities on different in vitro systems (T-cell proliferation induced by specific soluble antigens, bi-directional mixed lymphocyte reaction). In conclusion, we demonstrate an increment of sCTLA-4 in serum of patients with autoimmune thyroid diseases. Its possible pathogenetic role during autoimmune processes can be speculated: sCTLA-4 can specifically inhibit the early T-cell activation by blocking the interaction of CD80/CD86 with the co-stimulatory receptor CD28. Conversely, higher levels of sCTLA-4 could compete with membrane-bound CTLA-4 for CD80/CD86, in later T lymphocytes activation phase, causing a reduction of inhibitory signaling
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Differentiation
|2 NLM
|
| 650 |
|
7 |
|a B7-1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a B7-2 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD28 Antigens
|2 NLM
|
| 650 |
|
7 |
|a CTLA-4 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CTLA4 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Brizzolara, Renata
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Simone, Rita
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chiappori, Alessandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Milintenda-Floriani, Francesca
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pesce, Giampaola
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bagnasco, Marcello
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 123(2007), 2 vom: 15. Mai, Seite 190-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:123
|g year:2007
|g number:2
|g day:15
|g month:05
|g pages:190-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 123
|j 2007
|e 2
|b 15
|c 05
|h 190-8
|